All In Biotech

Free tool

FAERS Monitor: Qlosi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217836 or its brand name (Qlosi, Pilocarpine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

1,260

Serious

645

51% of reports

Hospitalization

274

Death reported

34

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective143
  • headache104
  • fatigue97
  • pain96
  • eye pain91
  • dyspnoea85
  • nausea80
  • dizziness76
  • diarrhoea74
  • off label use70
  • cough68
  • fall67
  • arthralgia62
  • product dose omission issue57
  • weight increased56

Reports by year received

View as table
YearReports
200417
200520
20066
20075
200815
200935
201043
20118
201214
201318
201415
201516
20167
201729
201840
201977
202093
202168
2022119
2023107
2024140
2025216
2026152

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,899 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
eye painSignal9127.022.12,252
weight increasedSignal564.23.2133
coughSignal684.03.2155
fallSignal673.42.7110
product dose omission issueSignal573.22.587
headacheSignal1042.82.3119
painSignal962.62.296
dizzinessSignal762.52.071
dyspnoeaSignal852.52.078
arthralgiaSignal622.52.055
fatigueSignal972.11.755
diarrhoea741.91.532
drug ineffective1431.81.655
nausea801.71.423
off label use701.31.16

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.